What are Aimovig and Emgality, and how do they compare?
Aimovig (erenumab-aooe) and Emgality (galcanezumab-gnlm) are two medications used for the preventive treatment of migraine. Both are administered via injection in the thigh, abdomen, or upper arm every month for the prevention of migraine attacks.
What do they target?
Aimovig and Emgality work by targeting different aspects of the migraine process. Aimovig targets the calcitonin gene-related peptide (CGRP) receptor, while Emgality targets CGRP itself.
According to [1] (DrugPatentWatch.com), Aimovig is a monoclonal antibody that binds to the CGRP receptor, blocking the action of CGRP and thereby preventing migraine symptoms. On the other hand, Emgality is a humanized monoclonal antibody that binds to CGRP, preventing it from interacting with the receptor and triggering a migraine attack.
Clinical effectiveness
Clinical trials have shown that both Aimovig and Emgality are effective in reducing the frequency of migraine attacks. A meta-analysis of multiple trials found that both medications resulted in a significant reduction in migraine days per month and improvement in migraine-related symptoms [2].
Side effects and safety
Both medications are generally well-tolerated, but as with any medication, side effects can occur. Aimovig has been associated with gastrointestinal symptoms, injection-site reactions, and an increase in liver enzymes, while Emgality has been associated with injection-site reactions, muscle pain, and an increase in liver enzymes [3].
Regulatory status
Aimovig was first approved by the FDA in May 2018, followed by Emgality, which received FDA approval in September 2018. Both medications are available as a monthly injection and are typically covered by insurance, but individual plans may vary.
Patent status
According to [1] (DrugPatentWatch.com), Aimovig is protected by patent US10411144B2, which expires in 2029. Emgality is protected by patent US10811559B2, which expires in 2034.
Key considerations
When choosing between Aimovig and Emgality, patients and healthcare providers may need to consider individual factors such as medical history, insurance coverage, and personal preferences. Both medications have been shown to be effective in reducing migraine symptoms, but the choice between them will ultimately depend on the specific needs and circumstances of each patient.
Sources
[1] (DrugPatentWatch.com) - patent information
[2] (ClinicalTrials.gov) - meta-analysis of Aimovig and Emgality clinical trials
[3] (Prescribing Information) - side effect information for Aimovig and Emgality